Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00726596 · ClinicalTrials.gov registry record · Phase 2
Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT00726596 is a Phase 2 study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 64 participants.
The verdict
NCT00726596, a Phase 2 study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This phase II trial studies how well hydroxychloroquine works in treating patients with previously treated prostate cancer. Autophagy destroys proteins and other substances in cells and may be used by prostate cancer cells to survive. Hydroxychloroquine, which blocks autophagy, may slow the growth of and possibly kill prostate cancer cells.
Interventions
- DRUG hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2008-08 |
| Est. Completion | 2018-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00726596
The ClinicalTrials.gov registry entry for NCT00726596 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hydroxychloroquine is the first listed.
NCT00726596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00726596 about?
NCT00726596 is a clinical study titled "Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer". This phase II trial studies how well hydroxychloroquine works in treating patients with previously treated prostate cancer. Autophagy destroys proteins and other substances in cells and may be used by prostate cancer cells to survive. Hydroxychloroquine, which blocks autophagy, may slow the growth o...
What is the current status of trial NCT00726596?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2008-08. Estimated completion is 2018-01.
What interventions are being tested in trial NCT00726596?
The interventions under investigation include: hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT00726596?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.